Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Celldex is developing targeted therapeutics to address devastating diseases for wh...
Celldex is developing targeted therapeutics to ...
Lianluo Smart Limited is a professional smart service products provider, which dev...
Lianluo Smart Limited is a professional smart s...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Founded 20 years ago, Seattle Genetics was built on a foundation of scientific inn...
Founded 20 years ago, Seattle Genetics was buil...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
We are a clinical stage biopharmaceutical company focused on the discovery, develo...
We are a clinical stage biopharmaceutical compa...
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiri...
MediciNova, Inc. is a publicly-traded biopharma...
Join the National Investor Network and get the latest information with your interests in mind.